Form 4: Prelude Therapeutics CEO Krishna Vaddi Acquires 675,000 Shares at $0.6925 Each

Prelude Therapeutics CEO Krishna Vaddi reports the acquisition of 675,000 shares of common stock at $0.6925 per share on March 25, 2025.

Summary

• On March 25, 2025, Krishna Vaddi, CEO of Prelude Therapeutics Inc., acquired 675,000 shares of common stock at a price of $0.6925 per share.
• Following this transaction, Vaddi directly owns 1,999,296 shares.
• Vaddi also has indirect ownership through various trusts and entities, including the Dolphin City Trust (423,655 shares), the Brocade Trust (551,774 shares), the Blue Sky Trust (551,776 shares), and Sidus Ventures LLC (142,553 shares).
• Vaddi disclaims beneficial ownership of the shares held by these trusts and entities, except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by the CEO. While insider buying can be seen as positive, it's important to consider the context and reasons behind the purchase.

Positives

• The CEO's purchase of a significant number of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when an insider of a publicly traded company buys or sells the company's stock. It provides transparency into the transactions of company executives and directors.

Key Dates

Keywords

Prelude Therapeutics, PRLD, Krishna Vaddi, CEO, stock acquisition, beneficial ownership, Form 4, insider trading